BTK and mantle cell lymphoma: Ibrutinib (Bruton's tyrosine kinase (BTK) inhibitor nowadays used for refractory chronic lymphocytic leukemia or mantle cell lymphoma (200) increases the risk of atrial fibrillation potentially via inhibition of cardiac PI3K-Akt signaling (201).